Thus, ACE2 is central in attenuating intrahepatic angiogenesis and intrahepatic sinusoidal resistance, and RAAS pathways could be pharmacologic targets for hepatic fibrosis [97]. This evidence concerns the gene ACE2 and Hepatic fibrosis.